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were randomized 3-14 days after the index AMI to EPL (25 mg titrated to 
50 mg QD; n=3319) or placebo (PBO; n=3313). Patients were followed 
for up to 2.5 years (mean=16 months)• End point analyses were per- 
formed with a Cox proportional hazards regression model with treatment 
group as the only factor, stratified by geographic region• Treatment-by- 
HR (_<90/>90 bpm) factor interaction was based on the Wald's test of 
the interaction term in the Cox model• 
The rate of all-cause mortality in PBO-treated patients was 25.2% in 
those with baseline HR >90 bpm and 15.9% with baseline HR _<90 
bpm. Reductions in risk with EPL relative to PBO according to baseline 
HR are in Figure• Although most of the treatment-by-factor interaction 
P-values were not significant, the reduction in risk for SCD in patients 
with HR >90 bpm was greater compared to patients with HR <90 bpm 
(treatment-by-factor interaction P-value=0.04). 
Figure i. Relative Risk of End points by Baseline HR. 
At an average of 16 months of follow-up, EPL treatment demonstrated a 
consistent effect on the risk of ACM, CVM/H, and CVM in EPHESUS 
patients with baseline HR _<90 and >90 bpm. While EPL treatment 
reduced the risk of SCD in patients with HR _<90 and >90 bpm, patients 
with a baseline HR > 90 bpm may derive a larger treatment effect for this 
end point• 
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In EPHESUS, treatment with eplerenone (EPL) significantly reduced 
mortality and morbidity in patients with acute myocardial infarction 
(AMI) and LVSD with signs of heart failure (HF) when used with stan- 
dard therapies• Because post-AMI HF patients often receive statin ther- 
apy, this retrospective analysis evaluated the treatment effect of EPL used 
concurrently with standard HF treatment in EPHESUS patients w /and  
w/out concomitant statin therapy• 
Patients w/post-AMI HF and LVEF </= 40% on standard therapy were 
randomized 3-14 days after index AMI to EPL (25 mg titrated to 50 
mg QD; N=3319) or placebo (PBO; N=3313) and followed for up to 
2.5 years. The comparative analyses of treatment effects in patients who 
received statins from baseline (from index AMI up to 14 days post-AMI) 
and those who did not were performed using a Cox proportional hazards 
regression analysis stratified by the geographical region• Treatment-by- 
statin interaction was tested using Cox model• 
Patients not on statin therapy appeared to have increased risk for end 
points compared with those on statins; the rate of all-cause mortality in 
PBO-treated patients was 19.5% and not on statins and 13.6% in those 
on statin therapy• Risk reductions with EPL relative to PBO for patients 
w /and  w/out concomitant statin therapy were similar (P >/=0•12) for 
each endpoint (Figure 1). There was no evidence of toxicity related to the 
coadministration of EPL and statins, and the incidence of adverse events 
with EPL was similar to PBO. 
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Figure L Relative Risk of Endpoints in EPHESUS by Baseline Statin Treatment. 
EPL treatment provided mortality and morbidity benefits in post-AMI HF 
patients w/and w/out concomitant statin therapy, with greater benefits in 
those receiving concomitant statin therapy• For each end point, event rates 
were lower with EPL than PBO, independent of statin treatment. 
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Introduction: heart failure (HF) is a frequent complication of acute 
coronary syndromes (ACS) and is associated with poor prognosis. Our 
goal was to find clinical parameters on admission that could predict HF, 
thereby helping select the most suitable management strategy. 
Methods: we studied 1045 patients (61.44-12.5 years-old, 71.7% males) 
consecutively admitted in our cardiology department with ACS. Clinical 
and laboratory parameters were obtained during the first 48 hours. The 
outcome was development of clinical signs of HF during hospitalisation. 
Results: cardiovascular risk factors were found in a significant propor- 
tion of our sample (hypertension in 55.9%, diabetes mellitus in 29.1%, 
current or previous smoking in 50%, dyslipidaemia in 62.2%, body mass 
index > 30 Kg/m 2 in 20%). Forty-three percent of the patients had ACS 
with ST segment elevation (STEMI) and 40% had left ventricular systolic 
dysfunction (LVSD). Multivessel and/or left main coronary artery disease 
were found in 52.3%. Revascularisation was performed in 60.7%. Heart 
failure occurred in 15.9%. Variables associated with development of HF 
in univariate analysis were: male sex (OR 0.446, 95%CI 0.317-0.629), 
age (OR 1.061, 95%CI 1.045-1.068), smoking (OR 0.463, 95%CI 0.328- 
0.655), hypertension (OR 1.528, 95%CI 1.083-2.157), diabetes (OR 
2.639, 95%CI 1.878-3.709), dyslipidaemia (OR 0.531, 95%CI 0.380- 
0.742), LVSD (OR 8.042, 95%CI 5.378-12.025), STEMI (OR 2.130, 
95%CI 1.519-2.987), revascularisation (OR 0.513, 95%CI 0.358-0.736), 
serum creatinine (OR 1.173, 95%CI 1.044-1.318), hematocrit (OR 0.9, 
95%CI 0.871-0.929), glycaemia (OR 1.07, 95%CI 1.05-1.091) and tro- 
ponin I (OR 1.004, 95%CI 1.002-1.006). Multivariate analysis, using a 
stepwise binary logistic regression method, revealed that the only ones 
with independent predictive value were: age (OR 1.056, 95%CI 1.036- 
1.076), LVSD (OR 6.381, 95%CI 4.009-10.156), STEMI (OR 1.628, 
95%CI 1.056-2.510), hematocrit (OR 0.916, 95%CI 0.882-0.952) and 
glycaemia (OR 1.064, 95%CI 1.039-1.090, for each 10 mg/dl increment). 
Using the predicted probabilities of this model we constructed a ROC 
curve. Its AUC was 0.85 (p < 0.001 vs ND). Using the best cut-off of pre- 
dicted probabilities this model showed a sensitivity of 88.3%, specificity 
of 64.5%, positive predictive value of 33% and negative predictive value 
of 96.7%. 
Conclusion: in-hospital post-ACS heart failure might be predicted on 
admission using common practice clinical and laboratory data. 
